



**FOR IMMEDIATE RELEASE**

## **SK life science Announces U.S. Availability of XCOPRI® (cenobamate tablets) CV for the Treatment of Partial-Onset Seizures in Adults**

*Company announces extensive patient access program, SK life science navigator*

**Paramus, New Jersey, May 11, 2020** – [SK Life Science, Inc.](#), a subsidiary of [SK Biopharmaceuticals Co., Ltd.](#), an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, announced today that XCOPRI® (cenobamate tablets) CV is now available by prescription in the U.S. XCOPRI was approved by the U.S. Food and Drug Administration (FDA) on November 21, 2019, for the treatment of partial-onset seizures in adults.

“Many adults with partial-onset seizures are still not able to control their seizures, even with the availability of many anti-epileptic drugs. That’s why we are proud to make XCOPRI available today as a new treatment option,” said Jeong Woo Cho, PhD, President and CEO of SK Biopharmaceuticals and SK life science. “We recognize that this is a very challenging time for the entire healthcare system, and we are committed to launching XCOPRI in a responsible way.”

To help patients prescribed XCOPRI get started and continue their therapy as appropriate, SK life science has developed an extensive new patient access program called SK life science navigator. For more information about how the program can assist eligible patients, visit [www.SKLSnavigator.com](http://www.SKLSnavigator.com). More information on XCOPRI is available at [www.XCOPRI.com](http://www.XCOPRI.com).

“Given the COVID-19 pandemic, we are supporting healthcare providers virtually, leveraging a suite of digital tools as well as video conferencing, to ensure they have an opportunity to gain important clinical and reimbursement information about XCOPRI. We are excited to begin face-to-face interactions as local markets allow,” said Seby Borriello, Chief Commercial Officer of SK life science. “This is a dynamic situation, so we will continue to monitor the environment and adjust our approach as appropriate.”

The efficacy and safety of XCOPRI have been studied in global clinical trials, including two randomized, double-blind, placebo-controlled studies (Study 013 and Study 017) and a large, multi-center, open-label safety study (Study 021). All three studies enrolled adults with uncontrolled partial-onset seizures, who were taking between one and three other anti-epileptic drugs (AEDs). In the randomized studies, XCOPRI demonstrated significant reductions in seizure frequency compared to placebo at all doses studied, and as many as one in five patients achieved zero seizures during the maintenance phase. The results of Study 017 were published in *The Lancet Neurology* in November 2019.

The most common ( $\geq 10\%$  and greater than with placebo) treatment-emergent adverse events associated with XCOPRI include somnolence (sleepiness), dizziness, fatigue, diplopia (double vision) and headache. See below for Important Safety Information.

### **About XCOPRI® (cenobamate tablets) CV**

XCOPRI is an anti-epileptic drug (AED) for the treatment of partial-onset seizures in adults. It was discovered and developed by SK Biopharmaceuticals and SK life science. In early 2019, SK Biopharmaceuticals entered into an exclusive licensing agreement with Arvelle Therapeutics to develop and commercialize cenobamate in Europe.

While the precise mechanism by which XCOPRI exerts its therapeutic effect is unknown, XCOPRI is believed to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. It is also a positive allosteric modulator of the  $\gamma$ -aminobutyric acid (GABA<sub>A</sub>) ion channel.

XCOPRI should be initiated at 12.5 mg once-daily and titrated every two weeks; it is available in six tablet strengths for once-daily dosing: 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg. XCOPRI can be combined with other AEDs or used alone.

### **IMPORTANT SAFETY INFORMATION AND INDICATION FOR XCOPRI® (cenobamate tablets) CV**

#### **DO NOT TAKE XCOPRI IF YOU:**

- Are allergic to cenobamate or any of the other ingredients in XCOPRI.
- Have a genetic problem (called Familial Short QT syndrome) that affects the electrical system of the heart.

#### **XCOPRI CAN CAUSE SERIOUS SIDE EFFECTS, INCLUDING:**

**Allergic reactions: XCOPRI can cause serious skin rash or other serious allergic reactions which may affect organs and other parts of your body like the liver or blood cells.** You may or may not have a rash with these types of reactions. Call your healthcare provider right away and go to the nearest emergency room if you have any of the following: swelling of your face, eyes, lips, or tongue, trouble swallowing or breathing, a skin rash, hives, fever, swollen glands, or sore throat that does not go away or comes and goes, painful sores in the mouth or around your eyes, yellowing of your skin or eyes, unusual bruising or bleeding, severe fatigue or weakness, severe muscle pain, frequent infections, or infections that do not go away. **Take XCOPRI exactly as your healthcare provider tells you to take it. It is very important to increase your dose of XCOPRI slowly, as instructed by your healthcare provider.**

#### **QT shortening: XCOPRI may cause problems with the electrical system of the heart (QT shortening).**

Call your healthcare provider if you have symptoms of QT shortening including fast heartbeat (heart palpitations) that last a long time or fainting.

**Suicidal behavior and ideation:** Antiepileptic drugs, including XCOPRI, may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call your health care provider right away if you have any of the following symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes in behavior or mood.

**Nervous system problems:** XCOPRI may cause problems that affect your nervous system. Symptoms of nervous system problems include: dizziness, trouble walking or with coordination, feeling sleepy and

tired, trouble concentrating, remembering, and thinking clearly, and vision problems. **Do not drive, operate heavy machinery, or do other dangerous activities until you know how XCOPRI affects you.**

**Do not drink alcohol or take other medicines that can make you sleepy or dizzy while taking XCOPRI without first talking to your healthcare provider.**

#### **DISCONTINUATION:**

**Do not stop taking XCOPRI without first talking to your healthcare provider.** Stopping XCOPRI suddenly can cause serious problems. Stopping seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus).

#### **DRUG INTERACTIONS:**

XCOPRI may affect the way other medicines work, and other medicines may affect how XCOPRI works. **Do not start or stop other medicines without talking to your healthcare provider.** Tell healthcare providers about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

#### **PREGNANCY AND LACTATION:**

XCOPRI may cause your birth control medicine to be less effective. **Talk to your health care provider about the best birth control method to use.**

**Talk to your health care provider if you are pregnant or plan to become pregnant.** It is not known if XCOPRI will harm your unborn baby. Tell your healthcare provider right away if you become pregnant while taking XCOPRI. You and your healthcare provider will decide if you should take XCOPRI while you are pregnant. If you become pregnant while taking XCOPRI, talk to your healthcare provider about registering with the North American Antiepileptic Drug (NAAED) Pregnancy Registry. The purpose of this registry is to collect information about the safety of antiepileptic medicine during pregnancy. You can enroll in this registry by calling 1-888-233-2334 or go to [www.aedpregnancyregistry.org](http://www.aedpregnancyregistry.org).

**Talk to your health care provider if you are breastfeeding or plan to breastfeed.** It is not known if XCOPRI passes into breastmilk. Talk to your healthcare provider about the best way to feed your baby while taking XCOPRI.

#### **COMMON SIDE EFFECTS:**

The most common side effects in patients taking XCOPRI include dizziness, sleepiness, headache, double vision, and feeling tired.

These are not all the possible side effects of XCOPRI. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. For more information, ask your healthcare provider or pharmacist. **Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088** or at [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

#### **DRUG ABUSE:**

**XCOPRI is a federally controlled substance (CV) because it can be abused or lead to dependence.** Keep XCOPRI in a safe place to prevent misuse and abuse. Selling or giving away XCOPRI may harm others and is against the law.

**INDICATION:**

XCOPRI is a prescription medicine used to treat partial-onset seizures in adults 18 years of age and older. It is not known if XCOPRI is safe and effective in children under 18 years of age.

Please see additional patient information in the [Medication Guide](#). This information does not take the place of talking with your healthcare provider about your condition or your treatment.

Please see full [Prescribing Information](#).

**About Epilepsy**

Epilepsy is a common neurological disorder characterized by seizures.<sup>1</sup> There are approximately 3 million adults in the U.S. living with epilepsy and approximately 60% have partial-onset seizures, which begin in just one part of the brain.<sup>3</sup> People with epilepsy are at risk for accidents and other health complications including falling, drowning, depression and sudden unexplained death in epilepsy (SUDEP).<sup>3,4</sup> Despite the availability of many anti-epileptic therapies, approximately 40% of adults with partial-onset seizures have inadequate control of their seizures, even after treatment with two anti-epileptic drugs (AEDs).<sup>2</sup>

**About SK Biopharmaceuticals Co., Ltd. and SK Life Science, Inc.**

SK Biopharmaceuticals and its U.S. subsidiary SK life science are global pharmaceutical companies focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS). The companies have a pipeline of eight compounds in development for the treatment of CNS disorders, including epilepsy. Additionally, SK Biopharmaceuticals is focused on early research in oncology. For more information, visit SK Biopharmaceuticals' website at [www.skbp.com/eng](http://www.skbp.com/eng) and SK life science's website at [www.SKLifeScienceInc.com](http://www.SKLifeScienceInc.com).

Both SK Biopharmaceuticals and SK life science are part of SK Group, one of the largest conglomerates in Korea. SK Holdings, the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Holdings is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses. For more information, please visit <http://hc.sk.co.kr/en/>.

*XCOPRI® is a registered trademark of SK Biopharmaceuticals Co., Ltd.*

###

**Media Contacts:**

**U.S. Media Inquiries**

SK Life Science, Inc.

[media@sklsi.com](mailto:media@sklsi.com)

**Korea Media Inquiries**

SK Biopharmaceuticals Co., Ltd.  
Gahye Kim  
[gahyekim@sk.com](mailto:gahyekim@sk.com)

---

1. Epilepsy Foundation. What Is Epilepsy? <https://www.epilepsy.com/learn/about-epilepsy-basics/what-epilepsy>. Accessed May 2020.
2. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment Outcomes in Patients with Newly Diagnosed Epilepsy Treated with Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study. <https://www.ncbi.nlm.nih.gov/pubmed/29279892>. Published online December 26, 2017.
3. National Institute of Neurological Disorders and Stroke. The Epilepsies and Seizures: Hope through Research. [https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Epilepsies-and-Seizures-Hope-Through#3109\\_9](https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Epilepsies-and-Seizures-Hope-Through#3109_9). Accessed May 2020.
4. Epilepsy Foundation. Staying Safe. <https://www.epilepsy.com/learn/seizure-first-aid-and-safety/staying-safe>. Accessed May 2020.